CoChat

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study

Open access
McConnachie, A., Walker, A., Robertson, M., Marchbank, L., Peacock, J., Packard, C. J., Cobbe, S. M., Ford, I. · 2014 · European Heart Journal

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

AIMS: To assess the impact on healthcare resource utilization, costs, and quality of life over 15 years from 5 years of statin use in men without a history of myocardial infarction in the West of Scotland Coronary Prevention Study (WOSCOPS). METHODS: Six thousand five hundred and ninety-five participants aged 45-54 years were randomized to 5 years treatment with pravastatin (40 mg) or placebo. Linkage to routinely collected health records extended follow-up for secondary healthcare resource utilization to 15 years. The following new results are reported: cause-specific first and recurrent cardiovascular hospital admissions including myocardial infarction, heart failure, stroke, coronary revascularization and angiography; non-cardiovascular hospitalization; days in hospital; quality-adjusted life years (QALYs); costs of pravastatin treatment, treatment safety monitoring, and hospital admissions. RESULTS: Five years treatment of 1000 patients with pravastatin (40 mg/day) saved the NHS £710 000 (P < 0.001), including the cost of pravastatin and lipid and safety monitoring, and gained 136 QALYs (P = 0.017) over the 15-year period. Benefits per 1000 subjects, attributable to prevention of cardiovascular events, included 163 fewer admissions and a saving of 1836 days in hospital, with fewer admissions for myocardial infarction, stroke, heart failure and coronary revascularization. There was no excess in non-cardiovascular admissions or costs (or in admissions associated with diabetes or its complications) and no evidence of heterogeneity of effect over sub-groups defined by baseline cardiovascular risk. CONCLUSION: Five years' primary prevention treatment of middle-aged men with a statin significantly reduces healthcare resource utilization, is cost saving, and increases QALYs. Treatment of even younger, lower risk individuals is likely to be cost-effective.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/eht232

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Cumulative incidence curves for cause specific admission to hospital [(A) for CABG or PCI, (B) for CHD, (C) for Heart Failure and (D) for Stroke], split by a randomized treatment group.
Figure 1 Cumulative incidence curves for cause specific admission to hospital [(A) for CABG or PCI, (B) for CHD, (C) for Heart Failure and (D) for Stroke], split by a randomized treatment group.CC BY-NC · PubMed Central
Figure 2 Figures showing the cumulative cardiovascular cost differences (A) and mean quality-adjusted life year differences (B) for pravastatin group - placebo group over time, with 95% confidence intervals. Estimates are shown as solid lines and 95% confidence bounds as dotted lines.
Figure 2 Figures showing the cumulative cardiovascular cost differences (A) and mean quality-adjusted life year differences (B) for pravastatin group - placebo group over time, with 95% confidence intervals. Estimates are shown as solid lines and 95% confidence bounds as dotted lines.CC BY-NC · PubMed Central
Figure 3 Plot of bootstrap results on the cost-effectiveness plane.
Figure 3 Plot of bootstrap results on the cost-effectiveness plane.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 2

  1. 1993, HEALTH BULL, 51, 72
  2. 2011, Canadian Medical Association Journal, 183, E1185

Cited by

See all 105

Metadata

Authors
McConnachie, A., Walker, A., Robertson, M., Marchbank, L., Peacock, J., Packard, C. J., Cobbe, S. M., & Ford, I.
Affiliations
  • University of Glasgow (GB)
  • National Health Service Scotland (GB)
  • Western Infirmary (GB)
  • Glasgow Royal Infirmary (GB)
Corresponding author
Ford, I.
Venue
European Heart Journal
Published
2013-07-09
Volume
35
Issue
5
Pages
290-298
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2162195068
Cited by
104
References
20
Citations by year
2026: 2 · 2025: 5 · 2024: 8 · 2023: 7 · 2022: 3 · 2021: 7 · 2020: 8 · 2019: 8 · 2018: 5 · 2017: 16 · 2016: 20 · 2015: 7 · 2014: 4 · 2013: 3
FWCI
11.18
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • European Heart Journal (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
Funders
  • Bristol-Myers Squibb
  • Wellcome Trust
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Keywords
statins, pravastatin, primary prevention, cardiovascular disease, healthcare resource utilization, cost-effectiveness, quality-adjusted life years, hospitalization, myocardial infarction, heart failure, stroke, coronary revascularization, middle-aged men, WOSCOPS, long-term follow-up
MeSH terms
Cardiovascular Diseases, Cost-Benefit Analysis, Health Resources, Hospitalization, Humans, Male, Middle Aged, Myocardial Infarction, Primary Prevention, State Medicine, Treatment Outcome, Pravastatin, Quality-Adjusted Life Years, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. https://app.cochat.ai/papers/10.1093/eurheartj/eht232
The paper
McConnachie, A., Walker, A., Robertson, M., Marchbank, L., Peacock, J., Packard, C. J., Cobbe, S. M., & Ford, I. (2014). Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. European Heart Journal. https://doi.org/10.1093/eurheartj/eht232

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.